These results demonstrated the drug efficacy of KX2-391 in inhibiting both cell growth and metastasis of NPC cells, indicating that SRC inhibition may be a promising approach to control the progression of NPC. This evidence concerns the gene SRC and nasopharyngeal carcinoma.